Trastuzumab biosimilar (Reliance Life Sciences)

曲妥珠单抗生物类似药 (Reliance Life Sciences)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab biosimilar (Reliance Life Sciences)
Drug Alias Name曲妥珠单抗生物仿制药 (Reliance Life Sciences)TrastuRelR-TPR-016
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2015/01/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesReliance Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesReliance Life Sciences
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC03
Related LinksN/A